Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia.

Ane Uranga\(^1\), Amaia Artaraz\(^1\), Amaia Bilbao\(^2\), Jose M. Quintana\(^3\), Ignacio Arriaga\(^2\), Maider Intxausti\(^2\), Jose Luis Lobo\(^4\), Julia Amaranta García\(^4\), Jesus Camino\(^5\), and Pedro Pablo España\(^1\)

\(^1\)Hospital Galdakao-Usansolo
\(^2\)Basurto University Hospital
\(^3\)Hosp Galdakao Usansolo
\(^4\)Araba University Hospital
\(^5\)Hospital San Eloy

June 24, 2020

Abstract

Rationale: The optimal duration of antibiotic treatment for community-acquired pneumonia (CAP) is not well established. The aim of this study was to assess the impact of reducing the duration of antibiotic treatment on long-term prognosis in patients hospitalized with CAP. Methods: This was a multicenter study assessing complications developed during one year of patients previously hospitalized with CAP who had been included in a randomized clinical trial concerning the duration of antibiotic treatment. Mortality at 90 days, at 180 days and at 1 year were analyzed, as well as new admissions and cardiovascular complications. A subanalysis was carried out in one of the hospitals by measuring C-reactive protein (CRP), procalcitonin (PCT) and proadrenomedullin (proADM) at admission, at day 5 and at day 30. Results: A total of 312 patients were included, 150 in the control group and 162 in the intervention group. 90 day, 180 day and 1-year mortality in the per-protocol analysis were 8 (2.57%), 10 (3.22%) and 14 (4.50%), respectively. There were no significant differences between both groups in terms of 1-year mortality (p=0.94), new admissions (p= 0.84) or cardiovascular events (p=0.33). No differences were observed between biomarker level differences from day 5 to day 30 (CRP p=0.29; PCT p=0.44; proADM p=0.52). Conclusions: Reducing antibiotic treatment in hospitalized patients with CAP based on clinical stability criteria is safe, without leading to a greater number of long-term complications.

INTRODUCTION

The optimal duration of antibiotic treatment in community acquired pneumonia (CAP) is not well established: discrepancies exist between the different guidelines published to date\(^1,2,3\). In 2007, IDSA / ATS included a minimum treatment of 5 days, provided the patient remains free of fever for 48-72 hours and without more than one criterion of clinical instability\(^4\). Recently published updated guidelines keep the same recommendation\(^5\).

The negative impact of the overuse of antibiotics is well known. In this regard, an increase in nasopharyngeal carriers of penicillin-resistant Streptococcus pneumoniae has been observed with the use of low-dose beta-lactams for more than 5 days in children. The unnecessarily prolonged use of antibiotics has been associated with a greater incidence of resistance, a higher number of adverse effects, worse adherence to treatment, and a higher cost\(^6-9\).

Several studies have been published with the aim of evaluating the safety of reducing the duration of antibiotic
treatment in patients with CAP\textsuperscript{10-13}. In a recent meta-analysis involving five clinical trials involving adults with mild-to-moderate CAP comparing the same types of antibiotic, short 3 to 7 day regimens of antibiotics were compared to 7 to 10 day regimens. The authors did not observe significant differences in terms of cure rate, mortality and adverse effects\textsuperscript{14}. Surprisingly, a new meta-analysis comparing \textsuperscript{15}6 day versus \textsuperscript{15}7 day regimens, observed a lower mortality rate in the shorter compared to the long regimen group (RR 0.52, 95% confidence interval [CI] 0.33 -0.82), with similar cure and relapse rates in both groups. When evaluating only the most severe patients, mortality was 2.2% in the group with a shorter regimen compared to 4.7% in the long regimen group.

On the other hand, the use of certain biomarkers such as procalcitonin (PCT) has been shown to be useful in reducing the duration of antibiotic treatment. In a study carried out with critically ill patients with CAP, an algorithm was implemented for the suspension of antibiotics in the event of a PCT reduction of at least 80% or with values of less than 0.5 ug / L\textsuperscript{16}. The authors observed an absolute difference of 2.7 days (95% CI 1.4-4.1, \(P <0.0001\)) between the group with which the PCT algorithm was implemented versus the control group, with a higher number of antibiotic-free days seen in the first group.

Recently, our working group published the positive results\textsuperscript{17} of a clinical trial designed to validate the IDSA / ATS criteria on the duration of antibiotic treatment in patients admitted for CAP. The median number of days with antibiotic in the control group was 10 as opposed to 5 in the intervention group, while the short-term clinical cure rate was similar for both groups. However, the impact that such a reduction may have on the long-term prognosis of these patients, as well as its effect on systemic inflammation, remains unknown.

The goal of the present study is to assess the impact in the long term of a reduction of antibiotic treatment in patients admitted for CAP. The method was to evaluate complications that occurred up to one year later in patients that had been included in a clinical trial for the validation of the IDSA / ATS criteria for the duration of antibiotic treatment.

METHODS

Study design

Multicentre cohort study, carried out in 4 hospitals in the Basque public network, which evaluated complications after one year in patients who had previously been included in a randomized clinical trial on the duration of antibiotic treatment in patients admitted for CAP. In the clinical trial intervention group, antibiotic treatment was prescribed for a minimum of 5 days and was suspended if for 48 hours the temperature was \(?73.78^\circ C\) and there was no more than 1 sign of clinical instability as defined by Halm’s clinical stability criteria (heart rate <100, respiratory rate <24, axillary temperature <37.2C, systolic blood pressure >90, saturation and \(O2>90\%\), good level of consciousness and tolerance of the oral route)\textsuperscript{5}. In the control group, the doctor decided on the duration of the antibiotic treatment. In a slight variance from established norms, the doctor him/herself chose the type of antibiotic. The follow-up period of the original clinical trial patients was 30 days, while the present study extended the follow-up period from 30 days to one year.

All patients were informed about the study and asked to give their informed consent. The project was approved by the Basque Country Ethics Committee (2011-001067-51).

Study patients

All adult patients (\(?18\) years) admitted for CAP and included in the clinical trial were included. Pneumonia was defined as a pulmonary infiltrate on chest X-ray not known to be old, and with symptoms indicative of pneumonia, such as cough, dyspnea, fever, and / or pleural pain. All patients previously excluded from the clinical trial due to infection by the human immunodeficiency virus were excluded, as well as the immunosuppressed (those with organ transplants or with splenectomy, those treated with 10mg/day of prednisone or equivalent for more than 30 days or with other immunosuppressive agents, neutropenic patients), those hospitalized in the previous 14 days, patients who received prior antibiotic treatment in the previous 30 days and institutionalized patients.
The study also excluded cases of pneumonia caused by infrequent agents (e.g., P. aeruginosa, S. aureus), infectious processes that required prolonged treatment with antibiotics (i.e., bacterial endocarditis, abscesses), pneumonia with pleural effusion that required drainage, those who died or who were admitted to the ICU before randomization and those who did not give their informed consent.

Data collection

At baseline, both demographic and clinical variables were collected for each patient. Severity was assessed using the PSI scale (pneumonia severity index)\(^\text{18}\). Comorbidity was collected using the Charlson comorbidity index\(^\text{19}\) and autonomy in activities of daily living was measured using the Katz index\(^\text{20}\). Vital signs were collected daily to assess clinical stability. Clinical cure and symptoms of pneumonia were assessed using a validated questionnaire\(^\text{21}\). Originally follow-up for all patients took place for up to 30 days, this period was extended to one year in this new study.

The main outcome variables that this study assessed were mortality at 90 days, 180 days, and 1 year, as well as new admissions that took place after the 30-day clinical trial follow-up and up to 1 year of index admission. Similarly, the occurrence of cardiovascular events was assessed during that same period of time, defined as the occurrence of hypertension, cardiac arrhythmia, valvulopathy, heart failure, coronary heart disease, decompensation of previous heart disease, intermittent claudication, thrombosis, embolism or stroke. The principal investigator at each hospital reviewed the medical records to confirm the occurrence of complications, in addition to conducting phone consultations when considered necessary. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

On the other hand, a subanalysis was carried out in one of the hospitals, where biomarker levels were measured at admission, at 5 days and at 30 days. PCR levels quantified by immunoturbidimetry with an analytical sensitivity of 1 mg/L were analyzed. PCT was analyzed via electrochemiluminescence, with an analytical sensitivity of 0.02 ng/mL and 5 pg/mL respectively. On the other hand, ProADM was analyzed via sandwich immunoassay using TRACE (time-resolved amplified cryptate emission) technology with an analytical sensitivity of 0.05 nmol/L.

Statistical analysis

For the descriptive analysis, frequencies and percentages were used for the qualitative variables, and mean and standard deviation (SD) or median and interquartile range (IQR) for the quantitative variables. Baseline characteristics of the intention to treat (ITT) population were compared between the control group and the intervention group. In addition, the main clinical outcomes up to one month follow-up in the per protocol population (PP) were compared between the two groups. The main results in follow-up up to one year were compared between the two groups using both ITT and PP. The main events were also compared between the different participating hospitals. To compare the qualitative variables the Chi-square test or Fisher’s exact test were used, whereas the t-test or Wilcoxon’s non-parametric test were used to compare the quantitative variables. Finally, the main outcomes were compared between the control group and the intervention group, adjusting for the Charlson comorbidity index, using the logistic regression model. Kaplan-Meier curves were drawn for one-year mortality in each group of patients and these were compared using the log-rank test.

Biomarker levels were compared between the two groups of patients on days 1, 5 and 30, as well as the difference from day 5 to day 30, using the Wilcoxon non-parametric test. Biomarker differences from day 5 to day 30 were also compared between the two groups of patients, adjusting for biomarker levels on day 5, using the general linear model. On the other hand, the effect of the difference in biomarkers from day 5 to day 30 on cardiovascular events at 1 year was analyzed, adjusting for biomarker levels on day 5 and the Charlson index, using the logistic regression model. Finally, we analyzed if this effect was different depending on the group. For this analysis, the logistic regression model was also used, considering the cardiovascular event as the dependent variable, and as independent variables: the difference in biomarker from day 5 to day 30, the group (intervention vs. control), the interaction between the difference and the group, as well as the adjustment variables for the Charlson index and the biomarker on day 5.
All results were considered statistically significant for $p < 0.05$. Analyses were performed using SAS for Windows, version 9.2 (SAS Institute, Cary, NC) and S-Plus 2000 (MathSoft Inc., Seattle, WA, 1999).

**RESULTS**

A total of 312 patients were included, 150 from the control group and 162 from the intervention group (Fig 1). 13 patients presented protocol violation in the intervention group. Likewise, 13 patients were lost during follow-up in the control group and 3 in the intervention group, leaving a total of 137 patients in the control group and 146 in the intervention group, in the per protocol analysis. Table 1 shows the baseline characteristics of the participants.

Table 2 shows the main results in the control and intervention groups. The overall mortality at 90 days, 180 days and 1 year per protocol was 8 (2.57%), 10 (3.22%) and 14 (4.50%), respectively. There were no significant differences in mortality after one year between both groups, both unadjusted and when adjusted for the Charlson comorbidity index (ITT: adjusted OR 0.89, 95% CI 0.30-2.69, $p=0.84$; PP: OR adjusted 1.04, 95% CI 0.33-3.26, $p=0.94$). The rate of new admissions per year in the control group was 27.01% while it was 25.52% in the intervention group, $p=0.84$. The same analysis was performed for each of the hospitals without showing any significant differences. Fig 2a and 2b show the analysis of 1-year survival by intention to treat (Hazard ratio (95% CI) $=0.91$ (0.32, 2.61), $p=0.87$), and per protocol (Hazard ratio (95% CI) $=1.08$ (0.36, 3.22), $p=0.89$), respectively, with no significant differences detected in either case. On the other hand, 16 (10.74%) cardiovascular events per year were observed in the control group and 23 (14.38%) in the intervention group (adjusted OR 1.40, 95% CI 0.71-2.77, $p$ value=0.33) in the per protocol analysis (Table 2).

A sample was obtained for biomarker analysis from 65 patients in the control group and 81 in the intervention group, all from one of the hospitals. The biomarker levels at admission, day 5, and day 30 as well as the difference from day 5 to day 30 are shown in Table 3. In the per protocol analysis, after adjusting for the value at day 5, no significant differences were observed between the control and intervention groups with respect to the difference in proadrenomedullin levels from day 5 to day 30 ($p=0.52$). Neither were significant differences detected for the PCR ($p=0.2910$) or in the PCT ($p=0.44$).

Last, the effect of change over time in biomarker values on the rate of cardiovascular events at follow-up was assessed (Table 4). 22 cardiovascular events were observed in this patient sample. Changes in proADM values from day 5 to day 30 showed an OR of 1.11 (95% CI: 0.09, 13.65) ($p$ of having any cardiovascular event, adjusted for its value on day 5 and by the Charlson index ($p=0.94$). The same analysis was performed taking into account the control and intervention groups, and again no significant effect was detected for cardiovascular events at 1 year in either the control or intervention group (proADM difference: $p=0.79$ and $p=0.86$, respectively; PCR difference: $p=0.38$ and $p=0.20$, respectively; and PCT difference: $p=0.94$ and $p=0.63$, respectively).

**DISCUSSION**

The main value of the current study is that it shows the medium and long-term safety of reducing the duration of antibiotic treatment in patients admitted for a case of CAP, based on clinical stability criteria, without leading to a greater number of long-term complications; nor did it lead to higher mortality or readmission rates, nor differences in the systemic inflammation presented by these patients. That is, the fact that there are no significant long-term differences in the main results under study between the control and intervention groups, validates our proposal to reduce the duration of antibiotic treatment in patients with clinically stable CAP from the point of view of the long-term safety of the patient.

The beneficial effects of reducing the duration of antibiotic treatment have been studied widely. On the one hand, it reduces antimicrobial resistance, possible adverse effects and costs, while, on the other hand, it improves adherence to treatment$^{6-9}$. However, despite current evidence, convincing clinicians to avoid unnecessarily prolonged guidelines remains an arduous task, likely due to a false sense of security provided by longer term treatments. In fact, a retrospective study carried out in the United States in patients admitted
for CAP, observed that the average duration of antibiotic treatment exceeded the recommended time by 74% and 71% for patients aged 18-64 years and [?] 65 years, respectively.22

A remarkable strength of this study is that it is based on a clinical trial with a unique design where the doctor him or herself decided on the type of antibiotic and in which similar cure rates were obtained for both groups. Likewise, unlike most of the studies published so far and despite the exclusion of patients requiring admission to Intensive Care, up to 40% of patients with IV and V PSI were included. However, the evidence for critically ill patients is limited. Chastre et al. carried out a double-blind clinical trial in patients with ventilator-associated pneumonia in which they compared 8-day versus 15 day antibiotic regimens. The authors observed no differences between the two groups except in the case of non-fermenting gram-negative germs. Recently, in a meta-analysis in which they compared regimens of [?] 6 days versus [?] 7 days with similar results, they carried out a sub-analysis in patients with severe pneumonia, observing lower mortality in the group with the shorter regimen (2.2% vs. 4.7%)15.

CAP has a great impact on systemic inflammation, both in the short and the long term. PCT has been the most widely studied biomarker for reducing antibiotic treatment. De Jong et al. conducted a clinical trial in critically ill patients in which the antibiotic was discontinued if the PCT value decreased by at least 80% or below 0.5 ug / L.25. The median number of days on antibiotics was 5 in the PCT group versus 7 days in the control group. Furthermore, the 1-year mortality in the PCT group was 36% as opposed to 43% in the control group (absolute difference 7.4, 1.3-13.8, p= 0.0188). However, the biomarker showing the best prognostic power for short and long-term complications in CAP has been proadrenomedullin.26-28. To this effect, in our study we were able to obtain a sample for biomarker analysis from 146 patients, without observing differences in biomarker levels between the control and intervention groups.

Mortality at 1 year after a case of CAP is high and it is thought that the cause may lie in a state of persistent chronic inflammation that leads to a greater number of cardiovascular events and higher long-term mortality.29-31. Undoubtedly, knowing the kinetics of biomarkers is crucial to measure the evolution of inflammation, proADM being the one biomarker that has shown the best results.26,32. For that reason, the evolution of biomarkers from day 5 to day 30 was analyzed, after adjusting for their baseline value, without obtaining significant differences between both groups, which supports the idea that the reduction of antibiotic treatment does not impact systemic inflammation.

Finally, our study has some limitations. First, data collection from 30 days to 1 year was done retrospectively. Second, few complications were observed in the sample with biomarkers, probably due to the small sample size. Third, the results cannot be extrapolated to the excluded population. Future studies assessing patients with those characteristics are necessary.

In conclusion, our study indicates that individualizing and reducing the duration of antibiotic treatment in patients with CAP based on clinical stability criteria is safe, without leading to a greater number of long-term complications or differences in systemic inflammation.

**Funding:** This study has received the following funding: SEPAR FELLOWSHIP (101/2016 Impact of the duration of antibiotic treatment on the long-term prognosis of patients admitted for community-acquired pneumonia); BBK-BIOCRUCES POST-MIR COURSE 2018-2019- BBK-BC / POST-MIR / 2018/007 FELLOWSHIPS.

**REFERENCES**

1. Menendez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodriguez de Castro F. Neumonia adquirida en la comunidad. Nueva normativa de la Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR). Arch Bronconeumol. 2010;46:543-58.

2. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009; 64 Suppl 3:iii1-55. [Medline]
3. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011; 17 Suppl 6:E1-59.

4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72.

5. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.

6. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroedan F, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998;279:365-70. [Medline]

7. Chalmers JD, Akram AR, Singanayagam A, Wilcox MH, Hill AT. Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. J Infect. 2016;73:45-53. [Medline]

8. Opmeer BC, El Moussaoui R, Bossuyt PM, Speelman P, Prins JM, de Borgie CA. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia. J Antimicrob Chemother. 2007;60:1131-6. [Medline]

9. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49:897-903.

10. Moussaoui R, De Borgie CAJM, Van den Broek P, Hustinx WN, BresseR P, Van den Berk GEL, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe CAP: randomized, double blind study. BMJ. 2006;332:1355-8.

11. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-dose, short-course levofloxacin for CAP: a new treatment paradigm. Clin Infect Dis. 2003;37:752-60.

12. Ignazio D, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrobial Agents and Chemotherapy. 2005;49(10):4035–41.

13. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: A meta-analysis. Am J Med. 2007;120(9):783-90.

14. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short- versus long-course antibiotic therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008;68:1841-54. [Medline]

15. Tansarli GS, Mylonakis E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. Antimicrob Agents Chemother. 2018;62. pii: e00635-18. doi: 10.1128/AAC.00635-18.

16. Boucha L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375:463-74.

17. Uranga A, Espana PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med. 2016;176:1257-65. [Medline]

18. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997;336:243-250.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Chronic Dis 1987;40:373-383.

20. Katz S, Ford AB, Moskowitz R, Jackson BA, Jaffe MW. Studies of illness in the aged: The index of ADL, a standardized measure of biological and psychosocial function. JAMA 1963;185:914–919.

21. Lamping DL, Schroter S, Marquis P, Marrel A, Duprat-Lomon I, Sagnier PP. The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia. Chest 2002;122:920-929.

22. Yi SH, Hatfield KM, Baggs J, Hicks LA, Srinivasan A, Reddy S, et al. Duration of antibiotic use among adults with uncomplicated community-acquired pneumonia requiring hospitalization in the United States. Clin Infect Dis. 2018;66:1333-41.

23. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 Days of Antibiotic Therapy for Ventilator-Associated Pneumonia in Adults. JAMA 2003;290:2588-2598.

24. Menendez R, Mendez R, Aldas I, Reyes S, Gonzalez-Jimenez P, Espana PP, et al. Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers. Chest 2019;156(6):1080-1091.

25. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819-27.

26. Kolditz M, Ewig S, Hoffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. The European respiratory journal. 2013;41(4):974-84.

27. Bello S, Fandos S, Lasierra AB, Minchole E, Panadero C, Simon AL, et al. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin. Respiratory medicine. 2015;109(9):1193-206.

28. Espana PP, Capelastegui A, Mar C, Bilbao A, Quintana JM, Diez R, et al. Performance of proadrenomedullin for identifying adverse outcomes in community-acquired pneumonia. J Infect. 2015 May;70(5):457-66.

29. Uranga A, Espana PP. Long-term mortality in community-acquired pneumonia. Arch Bronconeumol. 2018;54:412-3.

30. Mortensen EM. Potential causes of increased long-term mortality after pneumonia. The European respiratory journal. 2011;37(6):1306-7.

30. Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in hospitalized patients with community-acquired pneumonia. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2013;17(12):e1125-9.

31. Aliberti S, Ramirez JA. Cardiac diseases complicating community-acquired pneumonia. Current opinion in infectious diseases. 2014;27(3):295-301.

32. Mendez R, Aldas I, Menendez R.. Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). Review J. Clin. Med. 2020, 9(2), 549; https://doi.org/10.3390/jcm9020549

Table 1. Baseline characteristics of the patients.

|                  | Control group (n=150) | Intervention group (n=162) | p value |
|------------------|-----------------------|---------------------------|---------|
| Age, average (SD)| 66.27 (17.9)          | 64.72 (18.7)              | 0.46    |
| Sex, n (%)       |                       |                           | 0.86    |
|                          | Control group (n=150) | Intervention group (n=162) | p value |
|--------------------------|-----------------------|-----------------------------|---------|
| **Masculine**            | 95 (63.3)             | 101 (62.3)                  |         |
| **Femine**               | 55 (36.7)             | 61 (37.7)                   |         |
| **Tobacco, n (%)**       |                       |                             | 0.96    |
| Active smoker            | 32 (21.3)             | 36 (22.6)                   |         |
| Never smoked             | 68 (45.3)             | 71 (44.7)                   |         |
| Former smoker            | 50 (33.3)             | 52 (32.7)                   |         |
| **Alcohol intake habits, n (%)** |              |                             | 0.14    |
| **Comorbidities, n (%)** |                       |                             |         |
| Liver disease            | 4 (2.7)               | 4 (2.5)                     | 1.00    |
| Heart disease            | 38 (25.3)             | 39 (24.1)                   | 0.80    |
| Congestive heart failure | 14 (9.3)              | 12 (7.4)                    | 0.54    |
| Cerebrovascular disease  | 16 (10.7)             | 9 (5.6)                     | 0.10    |
| Kidney disease           | 12 (8.0)              | 12 (7.4)                    | 0.84    |
| COPD                     | 21 (14)               | 27 (16.7)                   | 0.51    |
| Diabetes mellitus        | 25 (16.7)             | 21 (12.0)                   | 0.36    |
| **Charlson Index, median (IQR)** |               |                             | 0.35    |
| **Katz Index**, average (SD) |                |                             | 0.22    |
| 0                       | 61 (40.7)             | 70 (43.2)                   |         |
| 1                       | 37 (24.7)             | 47 (29.0)                   |         |
| >1                      | 52 (34.7)             | 45 (27.8)                   |         |
| **Categorized PSI, n (%)** |                     |                             | 0.51    |
| I-III                   | 89 (59.3)             | 102 (63)                    |         |
| IV-V                    | 61 (40.7)             | 60 (37.0)                   |         |
| **PSI, average (SD)**    | 83.7 (33.7)           | 81.8 (33.8)                 | 0.63    |

Data are presented as average (SD), median (IQR) or n (%).

SD: Standard Deviation; IQR: Interquartile range

Katz Index: index that assesses the independence of the patient for activities of daily living, showing a higher score for greater dependence (range, 0 to 6).

Table 2. Main results in the control group (conventional treatment) and in the intervention group (duration of antibiotic treatment based on IDSA / ATS)
| CONTROL INTERVENTION OR (IC 95%) | p value |
|-------------------------------|---------|
| **PP** n=137 n=146 |         |
| 90 day Mortality 5 (3.68) | 3 (2.05) | 0.48 (0.11-2.19) | 0.35 |
| 180 day Mortality 5 (3.68) | 5 (3.42) | 0.85 (0.23-3.12) | 0.80 |
| 1 year Mortality 6 (4.41) | 7 (4.79) | 1.04 (0.33-3.26) | 0.94 |
| 1 year Admissions 37 (27.01) | 37 (25.52) | 0.95 (0.55-1.64) | 0.84 |
| 1 year CV events 14 (10.29) | 21 (14.58) | 1.50 (0.73-3.08) | 0.27 |

Data are presented as n (%).

OR= odds ratio, IC= confidence interval, CV=cardiovascular, ITT=Intention to treat, PP=Per protocol.

¶ OR is estimated by considering the control group as the reference group and adjusting for the Charlson comorbidity index.

**Table 3.** Biomarker levels in the control group (conventional treatment) and in the intervention group (duration of antibiotic treatment based on IDSA / ATS)

| ITT Control Intervention p value |
|-------------------------------|---------|
| **ITT n=65 n=81** |         |
| ProADM day 1 1.01 (0.78, 1.36) | 0.92 (0.68, 1.31) | 0.34 |
| ProADM day 5 0.84 (0.57, 1.03) | 0.81 (0.55, 1.17) | 0.68 |
| ProADM day 30 0.71 (0.49, 1.03) | 0.68 (0.48, 0.95) | 0.86 |
| ProADM difference from day 5 to day 30 -0.05 (-0.22, 0.01) | -0.09 (-0.18, 0.03) | 0.97 |
| PCR day 1 240.20 (97.50, 301.30) | 159.75 (87.30, 304.70) | 0.37 |
| PCR day 5 47.90 (25.10, 106.60) | 43.60 (16.90, 78.90) | 0.15 |
| PCR day 30 2.65 (1.60, 8.80) | 2.50 (1.40, 5.40) | 0.41 |
| PCR difference from day 5 to day 30 -39.90 (-84.90, -20.45) | -35.15 (-69.50, -13.70) | 0.40 |
| PCT day 1 0.70 (0.18, 3.34) | 0.49 (0.15, 2.09) | 0.59 |
| PCT day 5 0.19 (0.09, 0.50) | 0.17 (0.06, 0.84) | 0.86 |
| PCT day 30 0.04 (0.02, 0.06) | 0.04 (0.03, 0.06) | 0.87 |
| PCT difference from day 5 to day 30 -0.11 (-0.31, -0.03) | -0.18 (-0.84, -0.03) | 0.27 |
| **PP n=61 n=75** |         |
| ProADM day 1 1.01 (0.78, 1.32) | 0.91 (0.68, 1.25) | 0.41 |
| ProADM day 5 0.81 (0.57, 1.01) | 0.81 (0.54, 1.19) | 0.59 |
| ProADM day 30 0.70 (0.49, 1.01) | 0.68 (0.49, 0.93) | 0.93 |
| ProADM difference from day 5 to day 30 -0.07 (-0.23, 0.01) | -0.09 (-0.15, 0.03) | 0.65 |
| PCR day 1 240.20 (86.80, 301.30) | 159.75 (87.75, 302.60) | 0.47 |
| PCR day 5 47.50 (25.10, 88.50) | 37.10 (15.70, 79.30) | 0.20 |
| PCR day 30 2.55 (1.60, 7.80) | 2.50 (1.30, 5.40) | 0.48 |
| PCR difference from day 5 to day 30 -42.30 (-86.70, -21.90) | -32.45 (-73.35, -14.50) | 0.17 |
| PCT day 1 0.67 (0.18, 3.34) | 0.49 (0.15, 1.68) | 0.67 |
| PCT day 5 0.19 (0.09, 0.50) | 0.17 (0.06, 0.75) | 0.87 |
| PCT day 30 0.04 (0.02, 0.06) | 0.04 (0.03, 0.06) | 0.54 |
| PCT difference from day 5 to day 30 -0.12 (-0.40, -0.04) | -0.18 (-0.69, -0.03) | 0.49 |

Data are presented as median (IQR).

IQR= interquartile range, ITT=Intention to treat, PP=Per protocol.

**Table 4.** Effect of biomarker level differences from day 5 to day 30 on cardiovascular events,
by intention to treat.

|                        | CV Events | CV Events |
|------------------------|-----------|-----------|
| **OR (95% CI)**        | **p value** |
| ProADM Difference      | 1.11 (0.09, 13.65) | 0.94 |
| PCR Difference         | 1.00 (0.99, 1.01)  | 0.57 |
| PCT Difference         | 0.28 (0.004, 20.04) | 0.56 |

OR= odds ratio, IC= confidence interval. CV: cardiovascular

$\uparrow$ OR is adjusted for the Charlson comorbidity index and the biomarker level on the 5th day.

**Fig 1. Study flow diagram.** ITT: intention-to-treat; PP: per protocol.

**Fig 2a. Kaplan-Meier Curves for 1-Year Mortality in the Intention To Treat Analysis.** The log-rank test did not show significant differences between both groups (control group with conventional treatment and intervention group with duration of antibiotic treatment based on IDSA / ATS); Hazard ratio (95% confidence interval) =0.91 (0.32, 2.61), p=0.87.

**Fig 2b. Kaplan-Meier Curves for 1-Year Mortality in Per-Protocol Analysis.** The log-rank test did not show significant differences between both groups (control group with conventional treatment and intervention group with duration of antibiotic treatment based on IDSA / ATS); Hazard ratio (95% confidence interval) =1.08 (0.36, 3.22), p=0.89.

**Hosted file**

Figure1.docx available at https://authorea.com/users/336330/articles/462052-impact-of-reducing-the-duration-of-antibiotic-treatment-on-the-long-term-prognosis-of-community-acquired-pneumonia

**Hosted file**

Figure 2a and 2b.docx available at https://authorea.com/users/336330/articles/462052-impact-of-reducing-the-duration-of-antibiotic-treatment-on-the-long-term-prognosis-of-community-acquired-pneumonia